Abstract |
To be clinically efficacious, nanotherapeutic drugs need to reach disease tissues reliably and cause limited side effects to normal organs and tissues. Here, we report a proof-of-concept study on the development of a smart peptidic nanophototherapeutic agent in line with clinical requirements, which can transform its morphology from nanoparticles to nanofibrils at the tumor sites. This in vivo receptor-mediated transformation process resulted in the formation and prolonged tumor-retention of highly ordered (J-aggregate type of photosensitizer) photosensitive peptide nanofibrillar network with greatly enhanced photothermal and photodynamic properties. This strategy of "multiple daily low-intensity laser radiation after each intravenous injection of significantly low-dose of nanomaterials" demonstrated effective elimination of 4T1 orthotopic syngeneic breast cancer in mice. The technology for nanomaterial modulation based on living cell surface receptors, in this case tumor-associated α3β1 integrin, has great potential for clinical translation and is expected to improve the therapeutic efficacy against many cancers.
|
Authors | Lu Zhang, Yi Wu, Xingbin Yin, Zheng Zhu, Tatu Rojalin, Wenwu Xiao, Dalin Zhang, Yanyu Huang, Longmeng Li, Christopher M Baehr, Xingjian Yu, Yousif Ajena, Yuanpei Li, Lei Wang, Kit S Lam |
Journal | ACS nano
(ACS Nano)
Vol. 15
Issue 1
Pg. 468-479
(01 26 2021)
ISSN: 1936-086X [Electronic] United States |
PMID | 33332957
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Animals
- Cell Line, Tumor
- Mice
- Nanoparticles
- Photochemotherapy
- Photosensitizing Agents
(pharmacology)
|